All In Biotech

Drug Trial Radar · NCT04732065

ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors

Open Label Phase 1 and Target Validation Study of ONC206 in Children and Young Adults With Newly Diagnosed or Recurrent Diffuse Midline Glioma (DMG), and Other Recurrent Primary Malignant Central Nervous System (CNS) Tumors

Last checked: Nov 19, 2026Latest source record: Jun 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

208

Planned (sponsor's estimate)

Start

Aug 23, 2021

Primary completion

May 31, 2027

Study completion Jul 31, 2027

Sponsor

Lead sponsor
Sabine Mueller, MD, PhDAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Jazz Pharmaceuticals; Mithil Prasad Foundation; Storm the Heavens Fund; The ChadTough Defeat DIPG Foundation; National Cancer Institute (NCI); Dana-Farber Cancer Institute
First posted
Feb 1, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years, up to 21 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase I trial studies the effects and best dose of ONC206 alone or in combination with radiation therapy in treating patients with diffuse midline gliomas that is newly diagnosed or has come back (recurrent) or other recurrent primary malignant CNS tumors. ONC206 is a recently discovered compound that may stop cancer cells from growing. This drug has been shown in laboratory experiments to kill brain tumor cells by causing a so called "stress response" in tumor cells. This stress response causes cancer cells to die, but without affecting normal cells. ONC206 alone or in combination with radiation therapy may be effective in treating newly diagnosed or recurrent diffuse midline gliomas and other recurrent primary malignant CNS tumors.

Conditions

  • Diffuse Midline Glioma (DMG)
  • Glioblastoma
  • Recurrent Ependymoma
  • Recurrent Malignant Central Nervous System Neoplasm
  • Spinal Cord Glioma
  • World Health Organization (WHO) Grade III Glioma
  • CNS Tumor
  • Central Nervous System Tumor

Interventions

  • ONC206Drug

    Given orally (PO)

  • Standard of Care Radiation TherapyRadiation

    Undergo RT

  • Optional Proton (1H) MR spectroscopy (MRS)Procedure

    Optional imaging procedure

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants with dose-limiting toxicities (DLT)Time frame: Within 4 weeks after first dose
  2. Maximum tolerated dose (MTD) of ONC206Time frame: Within 4 weeks after first dose

Locations

7 sites in 3 countries. Site status is shown where the registry gives one.

  • University of California, San Francisco

    San Francisco, California · Recruiting

  • Children's National Hospital

    Washington D.C., District of Columbia · Recruiting

  • Emory University

    Atlanta, Georgia · Recruiting

  • University of Michigan

    Ann Arbor, Michigan · Recruiting

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania · Recruiting

  • Princess Máxima Center for Pediatric Oncology

    Utrecht, Netherlands · Recruiting

  • The University Children's Hospital in Zurich

    Zurich, Canton of Zurich, Switzerland · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.